BioLineRx Ltd (BLRX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, BioLineRx Ltd (BLRX) has a cash flow conversion efficiency ratio of -0.196x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.26 Million) by net assets ($16.62 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market value of BioLineRx Ltd for the company's overall valuation and market capitalisation.
BioLineRx Ltd - Cash Flow Conversion Efficiency Trend (2008–2025)
This chart illustrates how BioLineRx Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
BioLineRx Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of BioLineRx Ltd ranked by their cash flow conversion efficiency. Explore BioLineRx Ltd (BLRX) cash earnings ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Nagarjuna Fertilizers and Chemicals Limited
NSE:NAGAFERT
|
0.074x |
|
Fourth-Link Inc.
KQ:056730
|
0.045x |
|
Field Solutions Holdings Ltd
AU:FSG
|
0.158x |
|
Dinamik Isi Makina Yalitim Malzemeleri Sanayi ve Ticaret AS
IS:DNISI
|
-0.013x |
|
ADX Energy Ltd
AU:ADX
|
-0.118x |
|
Daedong Metals Co. Ltd
KQ:020400
|
-0.060x |
|
Japan Vietnam Medical Instrument JSC
VN:JVC
|
0.005x |
|
CEL-SCI Corp
NYSE MKT:CVM
|
-0.361x |
Annual Cash Flow Conversion Efficiency for BioLineRx Ltd (2008–2025)
The table below shows the annual cash flow conversion efficiency of BioLineRx Ltd from 2008 to 2025. View BioLineRx Ltd (BLRX) stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $23.34 Million | $-8.14 Million | -0.349x | +89.30% |
| 2024-12-31 | $13.46 Million | $-43.87 Million | -3.259x | -90.63% |
| 2023-12-31 | $13.22 Million | $-22.61 Million | -1.710x | -231.27% |
| 2022-12-31 | $50.84 Million | $-26.24 Million | -0.516x | -49.07% |
| 2021-12-31 | $68.09 Million | $-23.57 Million | -0.346x | +67.13% |
| 2020-12-31 | $22.03 Million | $-23.21 Million | -1.053x | -55.13% |
| 2019-12-31 | $33.38 Million | $-22.67 Million | -0.679x | -15.98% |
| 2018-12-31 | $41.32 Million | $-24.19 Million | -0.585x | -50.68% |
| 2017-12-31 | $52.88 Million | $-20.55 Million | -0.389x | +6.22% |
| 2016-12-31 | $35.03 Million | $-14.51 Million | -0.414x | -39.23% |
| 2015-12-31 | $47.61 Million | $-14.17 Million | -0.298x | +34.72% |
| 2014-12-31 | $31.77 Million | $-14.48 Million | -0.456x | +73.68% |
| 2013-12-31 | $11.68 Million | $-20.23 Million | -1.732x | -28.90% |
| 2012-12-31 | $14.97 Million | $-20.11 Million | -1.344x | -169.77% |
| 2011-12-31 | $22.53 Million | $-11.22 Million | -0.498x | -261.89% |
| 2010-12-31 | $37.26 Million | $11.46 Million | 0.308x | +144.52% |
| 2009-12-31 | $31.13 Million | $-21.51 Million | -0.691x | +48.70% |
| 2008-12-31 | $20.75 Million | $-27.96 Million | -1.347x | -- |
About BioLineRx Ltd
BioLineRx Ltd., a biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes GLIX1, an oral, small molecule targeting DNA damage response in glioblastoma and other cancers; and APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the tr… Read more